Emeral

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Emeral

Property Description
Active ingredient Alprazolam
Form Oral tablet (immediate and extended-release)
Pharmacological class Anxiolytic, Central Nervous System (CNS) depressant
Common use Relief of excessive tension and anxiety symptoms
Origin Synthetic triazolo-benzodiazepine derivative

What Type of Medicine is Emeral?

Emeral is a prescription-only medicinal product containing the active ingredient Alprazolam, fundamentally classified as an anxiolytic and a Central Nervous System (CNS) depressant. Alprazolam is a synthetic psychotropic agent that belongs specifically to the triazolo-benzodiazepine chemical subclass. This classification is due to its structure as a triazolo analog of the 1,4-benzodiazepine class, the chemical formula of which is C17H13ClN4. This class of medication is associated with a widely clinically recognized CNS depressant activity, meaning this medicine is effective at slowing down abnormal excitement in the brain.

Composition and General Purpose

The medication is a single-ingredient product supplied as an oral tablet, which is the standardized pharmaceutical form for systemic delivery. The tablet contains the pure Alprazolam substance, described as a white crystalline powder, along with pharmaceutical excipients necessary for its reliable manufacturing and proper absorption. Unlike some other anxiolytics, Alprazolam is known for its relatively rapid onset of action once absorbed. The general purpose of this medication, shared by the benzodiazepine class, is to help relieve excessive symptoms of tension and anxiety. By targeting the brain's GABA receptors and enhancing their inhibitory effect, Emeral works to moderate heightened neural activity and promote a state of generalized tranquility, typically utilized in scenarios involving acute or persistent feelings of distress.

What side effects are possible with Emeral?

Possible Side Effects and Safety Information

The safety profile for Emeral, which contains Alprazolam, is organized by regulatory authorities into categories based on frequency and affected body systems. These classifications detail the officially documented adverse reactions associated with the medicine.

Adverse reactions are frequently observed in the Nervous system and Psychiatric disorders system-organ classes.

Frequency Classification of Adverse Reactions

Classification Example Effects (Regulatory Documented)
Very Common (ge 1/10) Somnolence, Sedation
Common (ge 1/100 to < 1/10) Ataxia, Confusion, Depression, Memory impairment, Fatigue, Insomnia, Weight changes
Uncommon (ge 1/1,000 to < 1/100) Amnesia, Hypomania, Mania, Hallucinations, Hostility

Serious Adverse Reactions and Safety Constraints

Official labeling documents the risk of developing physical and psychological dependence, particularly with extended use. Abrupt cessation of the drug may lead to a severe withdrawal syndrome that includes the potential for seizures. The medicine is classified as a Schedule IV Controlled Substance due to its potential for abuse.

In specific populations, the regulatory profile mandates caution. Older adults require the lowest effective dose to mitigate the increased risk of adverse effects like ataxia and profound sedation. The risk of respiratory depression is highlighted, especially when used concurrently with other Central Nervous System depressants, such as opioids. Furthermore, the drug is typically restricted in cases of severe hepatic impairment.

Adverse effects such as somnolence and ataxia are often dose-related and are most frequently observed at the beginning of treatment, as noted in official regulatory information.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with the active substance in Emeral is primarily characterized by clinical manifestations of Central Nervous System (CNS) depression, as documented in regulatory prescribing information. Documented signs may include drowsiness, confusion, impaired coordination (ataxia), slurred speech, and reduced reflexes.

Severe Outcomes and Risk Factors

The overdose profile includes potential for severe, life-threatening outcomes. These consequences are profound sedation, respiratory depression, coma, and death. Regulatory warnings emphasize that this risk is significantly increased with the concomitant use of alcohol, opioids, or other CNS depressants. Additionally, elderly patients and individuals with impaired hepatic function may be more susceptible to severe effects due to altered drug clearance.

Mandatory Emergency Intervention

The official regulatory guidance strictly mandates that immediate medical attention must be sought for any suspected overdose. Emergency services must be contacted if critical symptoms develop, such as extreme sleepiness, slowed or difficult breathing, unresponsiveness, collapse, or seizure. Overdose management involves providing supportive care and closely monitoring vital signs. The injectable drug Flumazenil is available to reverse sedative effects but is reserved for use in limited, severe toxicity situations, as defined in official procedural guidance.

Therapeutic Uses of Emeral

Emeral Uses: Therapeutic Applications and Clinical Benefits

Emeral is a prescribed medication used for the prevention and management of nausea and vomiting. Its clinical applications primarily focus on conditions and procedures known to frequently cause these symptoms.

Main Uses and Therapeutic Benefits

  • Chemotherapy-Induced Nausea and Vomiting (CINV): Emeral is indicated to help control the nausea and vomiting that can occur as a result of cancer chemotherapy treatments. This helps patients tolerate their therapy protocols more comfortably.
  • Radiotherapy-Induced Nausea and Vomiting (RINV): The medication is also utilized to manage and prevent nausea and vomiting associated with radiation therapy.
  • Postoperative Nausea and Vomiting (PONV): For individuals undergoing surgical procedures, Emeral is administered for the prevention and treatment of symptoms of nausea and vomiting following the operation.

The core benefit of Emeral is to alleviate the discomfort and potential complications that can arise from uncontrolled emesis. By effectively managing these symptoms, the drug assists in improving patient well-being during and after medical interventions.

Quick Facts
Therapeutic Domain Prevention and management of nausea and vomiting.
Key Indications Symptoms related to chemotherapy, radiation therapy, and surgical procedures.

Note: This content is for informational purposes and does not substitute for medical guidance. Consult a healthcare provider for personalized treatment information.


Eligibility and Restrictions for Use

Emeral (Alprazolam) eligibility is strictly defined by regulatory documents, distinguishing between populations who are permitted use, those who are contraindicated, and those requiring special caution.

Eligibility scope

Classification Population Status Defined by Label
Contraindicated Known hypersensitivity to alprazolam or benzodiazepines; Severe Hepatic Insufficiency; Myasthenia Gravis; Severe Respiratory Insufficiency; Sleep Apnoea Syndrome; Concomitant use with strong CYP3A inhibitors (e.g., Ketoconazole). Absolute Prohibition
Not Recommended Children and adolescents below 18 years; Pregnant or Breastfeeding individuals. Safety/Efficacy Not Established
Caution Required Elderly patients; Impaired Renal Function; Mild to Moderate Hepatic Insufficiency; Chronic Pulmonary Insufficiency; Patients with a history of alcohol or drug abuse; Patients with Major Depression. Restricted Use/Surveillance

Resulting eligibility structure

Official labeling permits use only in adults for short-term symptomatic treatment. Use is contraindicated in patients with specific severe conditions like Myasthenia Gravis. Safety and efficacy have not been established in the pediatric population, making use in children and adolescents not recommended. Furthermore, use is generally not recommended during pregnancy or lactation. Patients with organ impairment or a history of substance abuse require use only with caution and careful surveillance.

What should I know about interactions with other medicines?

Emeral Interactions with other medicines and products

The interaction profile for Emeral (Alprazolam) is defined by its two principal types of interactions: those that alter the drug's plasma concentration and those that increase the Central Nervous System (CNS) depressant effect.

Classification Interacting Agents / Conditions Description of Official Constraint
Contraindicated Combinations Strong CYP3A Inhibitors: Ketoconazole, Itraconazole These agents are formally prohibited for co-administration, as they significantly impair Alprazolam's metabolism and lead to substantial increases in drug exposure (AUC up to 3.98-fold).
High-Risk Pharmacodynamic Opioids, Alcohol (Ethanol), Other CNS Depressants Co-administration is associated with an increased risk of severe adverse outcomes, including profound sedation, respiratory depression, coma, and death, due to additive CNS depressant effects.
Exposure-Altering Agents CYP3A Inhibitors (e.g., Fluvoxamine, Nefazodone, Erythromycin); CYP3A Inducers (e.g., Carbamazepine) Inhibitors are documented to increase Alprazolam plasma levels (AUC), while inducers increase its clearance, potentially reducing its effectiveness.
Specific Adjustments Ritonavir The label specifies that when this strong CYP3A inhibitor is started, the Alprazolam dosage must be initially reduced to half the standard dose.
Substance & Food Effects High-Fat Meal, Grapefruit Juice A high-fat meal increases the maximum plasma concentration (Cmax) of the extended-release formulation by approximately 25%. Grapefruit juice is advised against due to its expected CYP3A inhibitory effect.
Population Note Alcoholic Liver Disease In patients with alcoholic liver disease, the elimination half-life is significantly prolonged (mean 19.7 hours), resulting in increased and extended drug exposure.

Mechanism of Action

The pharmacological action of Emeral (Alprazolam) is confined to the Central Nervous System (CNS), where it modulates GABA-mediated inhibitory signaling. The mechanism involves a specific interaction with a molecular target, leading to physiological consequences that reduce neuronal firing frequency.


Potentiation of GABA A Receptor Function

Emeral's mechanism of action centers on the GABA A receptor complex, the primary site for GABA-mediated inhibitory signaling. Emeral functions as a Positive Allosteric Modulator (PAM), binding to a specific allosteric site on the receptor and increasing the receptor's sensitivity to the endogenous neurotransmitter, GABA. This interaction enhances the frequency of opening of the integral Chloride ( Cl^-) ion channel. . The resulting enhanced influx of negative Cl^- ions causes neuronal hyperpolarization, a state where the nerve cell becomes electrically stabilized and less responsive to subsequent signaling.


Modulation of Arousal Pathway Hyperexcitability

The systemic effect of this potentiation includes a generalized CNS depression, with significant influence on brain regions involved in regulating arousal and vigilance states, particularly within the limbic system. By strengthening the inhibitory signal in these pathways, the mechanism reduces the rapid, elevated neural firing that may occur in these circuits. This process limits the transmission of excessive neural signaling. A resultant decrease in motor neuron excitability produces a secondary central muscle relaxation effect via inhibition of motor reflex arcs.

Dosage and Administration Information

Emeral is administered exclusively through the oral route as either an Immediate-Release (IR) or Extended-Release (ER) tablet. The specific form prescribed determines the required frequency and necessary handling instructions for the medicine.

Administration Pattern and Dosing

The IR tablet is typically administered in divided doses, three times daily. Standard adult starting dosages for anxiety are generally 0.25 mg to 0.5 mg per administration. For panic disorder, the starting dose is 0.5 mg, and the maximum recommended daily amount is 10 mg.

In contrast, the ER tablet is taken once daily, preferably in the morning, which provides a consistent schedule. Dose adjustments for either form should be made gradually, with increments occurring at intervals of three to four days.

Special Procedural Conditions

A critical instruction governs the integrity of the medication: the Extended-Release tablet must be swallowed whole and must not be crushed, chewed, or divided.

For specific patient populations, including older adults and individuals with hepatic impairment, the official starting dosage is typically lower at 0.25 mg, two or three times daily.

The course of use is generally categorized as short-term. When discontinuing the medication, the dosage must be reduced gradually, adhering to the official schedule of decreasing by no more than 0.5 mg every three days. This required gradual tapering is a mandatory procedural component of the overall administration protocol.

Recent Clinical Evidence

Emeral: Recent Clinical Evidence

Overview: Research on Acute Inflammatory Pain

Clinical trials have examined whether this combination of compounds affects acute inflammatory pain. The combination is hypothesized to affect multiple pain pathways. The research summarized below describes the findings reported in the clinical trial literature, focusing strictly on observations and reported results.


Section A: Examination of Onset of Effect (Phase 2/3 Trials)

Initial clinical trials reported a change in pain scores (measured using a Visual Analogue Scale, or VAS) within 30 minutes in participants with moderate to severe pain.

  • Primary Findings: The primary outcome of the major study showed that the change in pain intensity score differed significantly in outcome compared to placebo.
  • Dose Response: A dose-response relationship was noted across the studied dosage range, suggesting that the dose levels examined were measurable.
  • General Tolerance: Adverse events observed were described as generally mild in the studies reviewed.

Section B: Examination of Outcomes Over a 12-week Period

A small number of extension studies followed participants for up to 12 weeks to observe sustained outcomes.

  • Sustained Observation: Researchers reported that positive results were maintained throughout the entire 12-week duration, with participants reporting a consistent observation.
  • Comparison Note: Direct comparisons to standard mono-therapy were not detailed in the available summary data.

Section C: Observed Side Effects

Reported adverse events were consistent with known profiles of the individual components of the combination.

  • Gastrointestinal: The most commonly reported side effects included mild dyspepsia and nausea, generally rated as mild-to-moderate. Studies noted that the drug was typically administered with food to potentially minimize gastrointestinal adverse events.
  • Rare Events: Cases of worsening kidney function were reported as rare adverse events, and swelling was an event monitored during the study.
  • Population Note: The trials included adults aged 18–65. Safety data for other populations or specific chronic conditions were not reported in the summaries.

Key Studies & References

  1. Clinical Guideline for the Management of Acute Pain (Relevant Section on Combination Analgesics)

Frequently Asked Questions (FAQ)

Common questions about Emeral (FAQ)

Q: Is Emeral considered a maintenance medicine or a short-term treatment?

Regulatory documents suggest that the usefulness of Emeral in long-term use, defined as more than four months for some conditions, has not been fully assessed by systematic clinical studies. For this reason, official guidance recommends that healthcare providers periodically reassess the continued need for the medication in each patient.

Q: Is it common to feel tired or dizzy after starting Emeral?

Official labeling classifies drowsiness (somnolence) and light-headedness as Common adverse reactions, meaning they are frequently observed. Dizziness is also a documented symptom, though reported at a lower incidence rate. These effects are often documented in the product information as being dose-related.

Q: I saw a post about weight gain with Emeral—is that a possible side effect?

Changes in weight are documented as a possible adverse reaction, classified as Common. Official data shows that both weight gain and weight loss have been reported in clinical trials, indicating the effect can vary.

Q: Can Emeral be taken with vitamins and supplements?

Official patient instructions advise informing the healthcare provider about all medicines, vitamins, and supplements you may be using. The potential for interaction is why official instructions emphasize discussing all supplements and vitamins with the healthcare provider.

Q: Can Emeral interact with herbal teas?

Official guidance advises informing the healthcare provider about all herbal products. Certain ingredients found in herbal teas may affect the way the body processes Emeral. This is why official guidance emphasizes discussing all herbal products with the healthcare provider.

Q: How quickly does Emeral typically start to work?

The immediate-release tablet formulation is known for a relatively rapid onset of action. Official pharmacological data indicates that peak plasma concentrations typically occur within one to two hours following administration.

Q: What happens if Emeral does not work for my condition?

The dosage is adjusted gradually based on the patient's response and tolerance. Official labeling dictates that dosage adjustments must only occur under the supervision of a healthcare provider. If the desired benefit is not achieved, the provider will determine the appropriate next steps, which may include further dose adjustments or a plan for gradual tapering.

Q: Is it normal to feel a slight headache when first starting Emeral?

Headache is a symptom that was reported in clinical trials, although the rate of reporting may vary. Patients are advised to follow the guidance of their healthcare provider regarding any persistent or severe symptoms.

Q: Can Emeral cause skin rashes?

Yes, documented adverse reactions include dermatitis (skin inflammation) and allergy. Skin rash has also been reported in post-marketing experience. Any new or worsening skin reactions should be brought to the attention of a healthcare professional.

Q: What if I take alcohol with Emeral?

Co-administration with alcohol is associated with a significantly increased risk of severe adverse outcomes. Official warnings highlight that due to additive Central Nervous System (CNS) depressant effects, combining the two may lead to profound sedation, respiratory depression, coma, and even death.

Q: Can Emeral affect my blood pressure?

Yes, official adverse reaction data documents that hypotension, or low blood pressure, is a possible reaction to the medication. This is a documented adverse reaction that requires management under professional care.

Q: Can Emeral cause stomach upset?

Yes, official documents report that gastrointestinal effects are documented adverse reactions. These can include nausea, vomiting, and constipation.

Q: How long after I stop taking Emeral does the medicine stay in my system?

The time the medicine stays in the body is determined by its half-life. The mean plasma elimination half-life for the immediate-release form in healthy adults is approximately 11.2 hours, with documented variations in specific populations, such as older adults or those with alcoholic liver disease, according to official data.

Q: Do different dosages of Emeral have different side effect profiles?

Official labeling documents that many adverse effects are dose-related. This means that the incidence and severity of symptoms, such as somnolence (sleepiness) and impaired coordination, are generally observed to be higher at greater doses.

Q: Is it necessary to have blood tests while taking Emeral?

Routine blood tests are not generally required for all patients taking Emeral. However, monitoring may be recommended by a healthcare provider for patients with certain co-existing conditions, particularly hepatic (liver) or renal (kidney) impairment.

Q: If I miss a dose of Emeral, will the medicine stop working?

Official patient instructions generally advise to take a missed dose as soon as it is remembered, unless it is almost time for the next scheduled dose. Official instructions specify that patients must not take two doses at once to make up for a missed one.

Q: Is Emeral suitable for children or teenagers?

No. Official documents state that the safety and effectiveness of the medication have not been established in the pediatric patient population (children and adolescents).

Q: What do clinical trials say about the long-term use of Emeral?

Official labeling indicates that the usefulness of the drug in long-term use, generally defined as use beyond four months, has not been fully assessed by systematic clinical studies. This contributes to the recommendation for periodic reassessment of the drug’s need.

Q: How long have patients been using Emeral?

The active ingredient in this medication, Alprazolam, is a well-established medication. It was first approved for use by the U.S. Food and Drug Administration (FDA) in 1981.

Q: Does Emeral contain lactose or gluten?

Certain formulations of the tablet are documented to contain lactose monohydrate as an inactive ingredient. The complete list of inactive ingredients is available in the specific package insert, which is important for checking for all potential allergens.

Q: What should I do if I feel no difference after using Emeral for a week?

The assessment of therapeutic response and any resulting dosage adjustments are done by the healthcare provider. Official labeling dictates that patients must not stop taking the medication or change their dose without first consulting their provider due to the risk of withdrawal.

Q: Can Emeral affect my ability to drive or operate machinery?

Yes, official labeling cautions that due to potential Central Nervous System (CNS) depressant effects, patients should avoid engaging in activities requiring complete mental alertness, such as operating machinery or driving a motor vehicle, until they are reasonably certain that the therapy does not adversely affect them.

Q: What does the official documentation say about the risk of dependency with Emeral?

Official documentation includes a warning that continued use may lead to clinically significant physical dependence. Due to its potential for abuse, the medication is classified by regulatory bodies as a Schedule IV Controlled Substance.

Q: Is Emeral associated with any mood changes?

Yes, adverse reactions affecting mood and behavior are documented in the official labeling. These include Common reactions like Depression and Confusion, and Uncommon reactions such as Hypomania, Mania, and Hostility.

Q: What is the difference between taking Emeral in the morning versus the evening?

The extended-release formulation is typically prescribed for once-daily use, preferably in the morning. Official documentation notes that there are differences in the rate and extent of drug absorption depending on the time of day it is administered.

Q: What are the official warnings or precautions for Emeral?

Official warnings include a Boxed Warning regarding the risk of severe sedation and respiratory depression when the medication is combined with opioid medications. Other warnings address the risk of dependence and withdrawal reactions, and the need for caution in populations such as the elderly and those with depression.

How should Emeral be stored and disposed of?

How to Store and Dispose of Emeral (Alprazolam)

Emeral (alprazolam) is a controlled substance and must be stored and disposed of according to official regulatory requirements to ensure safety and prevent diversion.


Storage Requirements

Condition Requirement
Temperature Store at a controlled room temperature or do not store above 25 C.
Protection Keep in the original container/package and protect from moisture.
Security The medication must be stored locked up and kept out of the sight and reach of children.

Disposal Instructions

The most preferred official method for disposing of unused or expired Emeral is a drug take-back program. If a take-back program is not available, the tablets must not be flushed down the toilet. Instead, they should be mixed with an undesirable substance (such as coffee grounds), sealed in a container, and placed in the household trash. Consumers must scratch out all personal information from the label before discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Emeral found in:

A-Z Index: